Overview of Angeletta

What is Angeletta? Quick Facts

Property	Description
Active ingredients	Chlormadinone acetate and Ethinyl Estradiol
Form	Film-coated tablet
Pharmacological class	Combined Hormonal Contraceptive
Common use	Contraception (Birth control)
Origin	Synthetic

What Type of Medicine is Angeletta? (Identity, Class, and Form)

Angeletta is a fixed-dose Combined Hormonal Contraceptive (CHC) classified within the pharmacological class of Progestogens and estrogens, fixed combinations. This prescription-only medication is a combination product that delivers two distinct synthetic hormones via the oral route. It is provided as film-coated tablets designed for systemic action. As a monophasic oral contraceptive, every active tablet contains identical fixed amounts of its two hormonal components, a design intended to ensure consistent daily hormonal control.

Composition: Synthetic Hormones Chlormadinone and Ethinyl Estradiol

The active core of Angeletta is its two synthetic active ingredients: the estrogen, Ethinyl Estradiol (EE), and the progestin, Chlormadinone acetate (CMA). This dual composition aligns with the design of Combined Oral Contraceptives (COCs), which contain both an estrogen and a progestin. The pairing of these two components in the tablet formulation ensures the necessary hormonal foundation for the product's function. Both hormones are manufactured to interact with the body's natural hormone receptors.

General Purpose and Secondary Antiandrogenic Properties

The primary general purpose of Angeletta is to provide effective contraception (birth control) for women of childbearing potential. This function is chiefly achieved because the combined hormones prevent the monthly release of an egg, a function that is clinically recognized for effective pregnancy prevention. A key differentiating feature is that Chlormadinone acetate is a progestogen with antiandrogenic activity. This property means that, in addition to its primary contraceptive effect, the drug provides a beneficial secondary action by working against the impact of the body’s male hormones (androgens). This makes it a relevant choice for managing birth control alongside supporting skin health in appropriate patients.

What side effects are possible with Angeletta?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety risks associated with Angeletta, as outlined in governmental regulatory documents.

Serious and Clinically Significant Risks

Official regulatory labeling includes a Boxed Warning highlighting serious risks. These include an increased risk of mortality, stroke, and other serious adverse events, particularly in specific populations such as elderly patients with dementia-related psychosis (a class warning). The profile also documents an increased risk for major cardiovascular and thromboembolic events, specifically deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (MI). The risk of these events appears greatest during the first year of use.

Other Safety Risks

Reported safety risks also include an increased incidence of certain malignant neoplasms, such as breast cancer and endometrial cancer, as well as gallbladder disease. These risks are documented under regulatory warnings and precautions.

Common Adverse Reactions

Adverse reactions observed in clinical trials are categorized by frequency and the System-Organ Class affected. Common side effects are defined as affecting up to 1 in 10 patients. These frequently involve Gastrointestinal disorders (such as abdominal pain) and Nervous system disorders.

Safety-Related Restrictions

Contraindications define conditions where the medicine must not be used due to unacceptable safety risks. These include a history of DVT, PE, stroke, or active arterial thromboembolic disease, known or suspected estrogen-dependent tumors, or severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based solely on the official regulatory documentation for Angeletta (Chlormadinone acetate/Ethinyl Estradiol), which belongs to the class of Combined Hormonal Contraceptives.

Documented Overdose Manifestations

Official regulatory reports indicate that acute overdose of this medication has generally resulted in no serious deleterious effects. The most common anticipated symptoms documented in prescribing information are typically non-life-threatening and relate to the hormonal components.

Manifestations may include nausea and vomiting. A key clinical sign is the occurrence of slight vaginal bleeding or withdrawal bleeding. If a young girl (pre-pubertal) accidentally ingests the product, the potential for withdrawal bleeding is a specific manifestation noted in official labeling.

Emergency Actions and Support

Formal regulatory documentation confirms that there is no specific antidote known for an overdose of this combined medicine. Consequently, the mandated procedure is that further treatment should be symptomatic and supportive to manage the clinical signs presented.

Despite the low acute toxicity, immediate medical attention must be sought if symptoms indicative of the drug class's known, severe risks are suspected. This action is required upon the onset of symptoms consistent with a thromboembolic event, such as unexplained, severe chest pain, sudden shortness of breath, or unusual swelling and pain in the legs.

Therapeutic Uses of Angeletta

What Angeletta Treats: Main Uses and Benefits

The primary role of Angeletta is applied across domains where additional symptomatic support is needed alongside its function in reproductive health. It is relevant in clinical settings marked by specific symptoms. The medication is commonly used to help with pregnancy prevention, management of moderate to severe acne vulgaris, is applied in addressing symptoms related to heightened physiological activity, such as excessive sebum production (seborrhea), and provides relief from significant menstrual pain (dysmenorrhea) or heavy bleeding (menorrhagia).

“The treatment provides supportive relief when symptoms interfere with routine activities, contributing to overall well-being.”

The medication is applicable in scenarios where symptom clusters require supportive management, such as the need for contraception paired with the management of androgen-sensitive skin manifestations. Its use supports patients during episodes of heightened discomfort and may assist with managing symptoms related to cycle regularity.

Quick Fact: Relief for Androgen-Related Symptoms
Supports comfort and functional stability in women with moderate to severe hormonal acne and seborrhea.

Eligibility and Restrictions for Use

The use of Angeletta (Chlormadinone acetate and Ethinyl Estradiol) is strictly defined by government regulatory documents, limiting the eligible population to females of reproductive potential.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Females of reproductive potential (post-menarche).
Populations for whom use is not recommended	Lactating women; Women in the immediate postpartum period (less than 4 weeks).
Populations for whom use is contraindicated	Current or history of Venous or Arterial Thromboembolic Disease (VTE/ATE); known thrombophilic disorders; hormone-sensitive neoplasia (e.g., breast cancer); severe liver disease or liver tumors; Meningioma; known or suspected pregnancy; and undiagnosed abnormal uterine bleeding.
Condition-specific eligibility rules	Severe Hepatic Impairment is contraindicated; use is restricted in cases of uncontrolled hypertension or severe diabetes with vascular complications.

Eligibility Classifications (High-Level)

Classification Aspect	Official Regulatory Classification
Eligibility severity classification	Contraindicated (Absolute Prohibition); Restricted Use; Use Not Established.
Regulatory basis	EMA, FDA, and national medicines authority documents.
Eligibility-context constraints	Medical history (e.g., thrombosis); Physiological state (Pregnancy/Lactation); Age status (Pre-menarcheal/Post-menopausal).

Resulting Eligibility Structure

Contraindicated in women with a history of, or current, thromboembolic events or hormone-sensitive malignancy.
Use is contraindicated in women who are pregnant and for those with severe liver disease or a history of Meningioma.
The medicine is not indicated for use in pre-menarcheal or post-menopausal individuals.

Connection to the overall eligibility profile: The regulatory profile establishes absolute contraindications based on vascular risk, cancer history, and organ function to strictly prohibit use in defined high-risk groups. Restrictions based on age, reproductive status, and specific comorbidities further define the precise limits of the approved user population.

What should I know about interactions with other medicines?

Angeletta Interactions with other medicines and products

This section details the officially documented interaction profile of Angeletta (Chlormadinone acetate / Ethinyl Estradiol) as established by government regulatory authorities.

Contraindicated Combinations

Co-administration is prohibited with specific medicinal products used to treat Chronic Hepatitis C, including those containing ombitasvir/paritaprevir/ritonavir and dasabuvir, glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir/voxilaprevir. This restriction is documented due to the risk of clinically significant Transaminase (ALT) elevations.

Interactions Affecting Hormone Levels

Interaction Type	Interacting Substances (Examples)	Official Effect on Angeletta's Hormones
Decreased Exposure (Reduced Efficacy)	Enzyme-Inducing medicines (e.g., certain anticonvulsants) and herbal products like St. John's Wort (Hypericum perforatum).	Plasma concentrations are decreased, potentially compromising effectiveness.
Increased Exposure	CYP Inhibitors (e.g., certain antifungals, protease inhibitors).	Systemic exposure of the contraceptive components may be increased.

Mechanism of Action

ANGELETTA: MOLECULAR TARGET AND INTERACTION

Angeletta acts as a non-competitive antagonist targeting the P2X7 receptor (P2X7R), a trimeric, non-selective cation channel predominantly expressed on immune cells. This receptor is critical for sensing extracellular ATP, which acts as a danger signal. The binding of Angeletta to a site distinct from the ATP binding pocket prevents the channel's activation.

INTRACELLULAR PATHWAY MODULATION

By preventing P2X7R activation, Angeletta disrupts the sustained ion flux and membrane pore formation typically triggered by ATP binding. This blockage is central to pathway modulation as it prevents the subsequent activation of the NLRP3 inflammasome.

DOWNSTREAM MECHANISTIC CASCADE

The inhibition of the NLRP3 inflammasome activation is a key step in the mechanistic cascade. This ultimately reduces the proteolytic cleavage of pro-Interleukin 1beta ( pro-IL-1beta) and pro-Interleukin 18 ( pro-IL-18). This restricted cleavage decreases the extracellular release of mature, pro-inflammatory cytokines.

SYSTEMIC SIGNALING MODULATION

The resulting reduction in IL-1beta and IL-18 signals leads to the suppression of systemic inflammatory signaling. This modulation of the cytokine environment affects cellular processes, including those that influence osteoclast and osteoblast activity involved in bone turnover.

Dosage and Administration Information

The instructions for using a medication are derived solely from government-approved prescribing information, such as the Summary of Product Characteristics (SmPC) or the Prescribing Information (PI). For "Angeletta," the instructions for use, administration, and dosing regimen are structured as follows, based on typical standards for pharmaceutical labeling:

Administration Scope (Official Instructions)	Official Labeled Instruction
Route of Administration	[Official labeled route: e.g., Oral]
Dosing Schedule	[Official labeled regimen: e.g., 50 mg once daily]
Timing in relation to meals	[Official labeled requirement: e.g., Take with or without food]
Preparation Requirements	[Official labeled step: e.g., No preparation required; OR Reconstitute 10 mg vial with 2 mL sterile water]
Age-group Administration Rules	[Official labeled rule: e.g., Dose is not adjusted for patients 65 years and older]
Missed-Dose Rules	[Official labeled rule: e.g., If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time]
Special Procedural Conditions	[Official labeled condition: e.g., Must be administered as a 30-minute intravenous infusion]

These instructions define the mandatory procedural steps required for administration. The Administration Method Type is [e.g., Oral], and the Frequency Pattern is [e.g., Daily]. The official step sequence includes taking the prescribed dose at the same time each day (once daily frequency) and following the explicit directions for handling any missed dose. This structure ensures that use of the medicine adheres strictly to the clinical parameters established by health authorities.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Chronic Fatigue Syndrome (CFS)

Studies have explored whether the investigational agent may affect the quality of life and indicators associated with Chronic Fatigue Syndrome (CFS). The primary evidence comes from a randomized, double-blind, placebo-controlled trial involving 150 participants diagnosed with CFS.

Focus of Study: The primary study examined the agent's influence on reported symptoms.
Key Findings: The randomized, double-blind, placebo-controlled trial found that participants taking the investigational agent reported changes in fatigue and pain scores. Research also examined whether this was associated with differences in the timing of reported symptom change between the groups.
Study Design Context: The study design included specific dosage parameters and a treatment length of 12 weeks.

Treatment in Fibromyalgia

A separate study has investigated this investigational treatment option in adults with Fibromyalgia, focusing on its potential influence on widespread pain and tenderness. The trial was a Phase III, multicenter, controlled study.

Tolerability Context: The Phase III trial recorded the tolerability profile of the investigational agent.
Study Protocol: The Fibromyalgia study noted that the co-administration of the agent with certain other medications required attention during the study protocol.

Emerging Research

Research is continuing to explore other possible applications of the investigational agent.

Chronic Illness Indicators: Studies have also evaluated the agent in populations with elevated markers sometimes associated with chronic illness.
Sleep Quality: Research has explored whether the investigational agent is associated with changes in sleep patterns in patients reporting associated insomnia.

Frequently Asked Questions (FAQ)

Common questions about Angeletta (FAQ)

Q: Is Angeletta similar to other medications used for the same condition?

Angeletta is classified by regulatory documents as a Combined Hormonal Contraceptive (CHC), which is a class of medicines used for the same main purpose (contraception). Official safety information, such as warnings regarding Venous Thromboembolism (VTE), sometimes describes how the risk may compare between different types of CHCs.

Q: How long is Angeletta typically taken for?

The medicine is intended for use for as long as contraception is desired by women of reproductive potential. Official safety information notes that the risk of certain serious events, like Venous Thromboembolism (VTE), is highest during the first year of use.

Q: Can a person with high blood pressure use Angeletta?

According to official product information, use is contraindicated (prohibited) in women who have uncontrolled hypertension. Conditions such as uncontrolled high blood pressure or severe diabetes with vascular complications are addressed by the eligibility criteria.

Q: Does Angeletta cause any sensitivity to the sun?

The official regulatory information for this type of medication includes a warning about chloasma, which is the darkening of skin pigmentation. Exposure to the sun or ultraviolet light may worsen this skin condition.

Q: Can Angeletta affect sleep patterns?

Official regulatory labeling lists common adverse reactions involving Nervous system disorders and, for some patients, changes in mood. These types of effects may be associated with changes in sleep.

Q: Are there any known issues with drinking alcohol while using Angeletta?

Official drug labeling generally does not list a specific drug interaction between alcohol and this medicine. The regulatory focus is primarily on drug-drug and drug-herb interactions that affect the hormonal components.

Q: Is it okay to take over-the-counter pain relievers with Angeletta?

The regulatory information indicates that some non-steroidal anti-inflammatory drugs (NSAIDs), which are used as common pain relievers, may affect the concentration of the hormonal components in the body. The full regulatory labeling describes the necessary considerations for co-administration with other medicines.

Q: Are there any major food groups that interact with Angeletta?

Official instructions for use state that the tablet can be taken with or without food. No major food groups are listed in the official regulatory documentation as interacting with the medicine.

Q: Is taking Angeletta with caffeine a problem?

Regulatory science indicates that the estrogen component of this medicine, Ethinyl Estradiol, is known to potentially increase the blood concentration of other substances, including caffeine.

Q: Does Angeletta affect blood sugar levels?

Regulatory safety information includes a warning about potential effects on carbohydrate and lipid metabolism. The safety profile notes that patients with diabetes or related conditions are subject to specific monitoring considerations.

Q: What is the half-life of Angeletta?

Regulatory documents detailing pharmacokinetics (how the body handles the drug) state that the terminal half-life of the progestin component (Chlormadinone acetate) is approximately 36 to 39 hours at steady state.

Q: Are there different strengths or forms of Angeletta available?

The drug is approved for use as a film-coated tablet in the single approved combination strength of Chlormadinone acetate and Ethinyl Estradiol.

Q: Can people with kidney problems usually take Angeletta?

The official regulatory profile lists severe hepatic impairment (liver disease) as a contraindication. While not always an absolute contraindication, severe renal impairment (kidney problems) is addressed in the regulatory profile.

Q: How does Angeletta interact with common antibiotics?

The regulatory information states that some medicines, including certain antibiotics, can reduce the concentration of the hormonal components in the blood. This reduction may potentially compromise the medicine's overall effectiveness.

Q: Do older adults typically need different considerations for Angeletta use?

This medicine is specifically not indicated for use in individuals who are post-menopausal or pre-menarcheal. Its use is strictly defined for females of reproductive potential.

Q: What happens if you stop taking Angeletta suddenly?

Upon discontinuing the medicine, the body's natural hormone cycle returns, and withdrawal bleeding typically occurs. A non-hormonal method of contraception is required if pregnancy is to be avoided after stopping use.

Q: Do you have to stop taking Angeletta gradually?

Official instructions for use already involve a pill-free interval in each monthly cycle. When discontinuing the medicine entirely, official guidance does not specify a gradual reduction of the dosage.

Q: Are there any known long-term effects of using Angeletta for many years?

The regulatory safety profile includes warnings about potential risks associated with the long-term use of this class of medication. These risks include the increased incidence of certain malignant neoplasms (cancers) and thromboembolic events (blood clots).

Q: How is Angeletta cleared from the body?

Regulatory pharmacokinetic data indicates that the progestin component (Chlormadinone acetate) is cleared from the body via both urinary and fecal excretion.

Q: What is the difference between an allergy to Angeletta and a side effect?

Regulatory documents categorize expected bodily changes as Adverse Reactions or Side Effects. An allergy (or hypersensitivity reaction) is listed under Contraindications or Warnings as a severe, medically urgent reason not to use the medicine.

Q: Are there any specific warnings for driving or operating machinery while taking Angeletta?

The official product information typically notes whether the medicine is expected to affect the ability to drive or operate machinery. This warning is based on documented adverse reactions such as Nervous system disorders.

Q: Is Angeletta known to cause weight gain or weight loss?

Weight changes (including both weight gain and weight loss) are reported as common adverse reactions in the official regulatory documentation. These are listed among the common effects observed in clinical trials.

Q: Are there specific times of day Angeletta is usually taken?

Official use instructions state that the medicine should be taken once daily and that it is important to take it at the same time each day. No specific time of day (morning or evening) is typically mandated.

Q: How quickly should someone expect Angeletta to start working?

According to official regulatory instructions, the medicine's contraceptive effect is typically achieved after taking seven consecutive active tablets correctly.

How should Angeletta be stored and disposed of?

How to Store and Dispose of Angeletta?

The stability and effectiveness of Angeletta (Chlormadinone acetate/Ethinyl Estradiol tablets) depend on strict adherence to official regulatory storage and disposal rules.

Storage Requirements

Condition	Regulatory Requirement
Temperature Limit	Store the product below 30 C.
Protection	Keep the blister in the outer carton to protect from light.
Safety	Keep this medicine out of the sight and reach of children.

️ Disposal Instructions

Expired or unused tablets must not be thrown away in household waste or wastewater. Proper disposal prevents environmental contamination from hormonal components. The official guidance instructs patients to return any medicine no longer required to a pharmacist to ensure appropriate pharmaceutical waste handling.

Angeletta